Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of localized prostate cancer
• * Diagnosed within the past 6 months
• * T1 or T2 disease
• * Gleason score 5-8
• * Prostate-specific antigen no greater than 20 ng/mL
• Radical prostatectomy planned
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• More than 2 years
• Hematopoietic
• Hemoglobin greater than 9.0 g/dL
• Platelet count greater than 100,000/mm\^3
• Absolute neutrophil count greater than 1,000/mm\^3
• Hepatic
• SGPT and SGOT less than 3 times normal
• Bilirubin less than 3 mg/dL (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)
• Renal
• Creatinine less than 2.0 mg/dL
• Cardiovascular
• No venous thrombosis within the past year
• Other
• Patients must use effective barrier contraception
• No other medical condition that would preclude study therapy
• No known soy intolerance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• No concurrent hormonal therapy for prostate cancer
• Radiotherapy
• Not specified
• Surgery
• See Disease Characteristics
• Other
• No concurrent soy supplements
• No concurrent foods high in genistein
• No concurrent active therapy for neoplastic disorders